Key points are not available for this paper at this time.
3003 Background: Axi-cel, an anti-CD19 CAR T cell therapy, demonstrated significant clinical benefit and a manageable safety profile for pts with refractory large B cell lymphoma in ZUMA-1 (Neelapu Cheson et al. J Clin Oncol. 2007); concordance was measured as the percentage of pts whose IRC matched local. Results: As of 8/11/17, median follow-up (f/u) was 15.1 mo for the 101 pts treated with axi-cel. While the BOR of 82% at primary analysis (PA; median f/u 8.7 mo) by local remained consistent (83%) at long-term f/u (LTFU; median of 15.1 mo), complete response (CR) rates increased from 54% to 58% (Table). Out of 34 pts with partial response (PR) at 1 mo, 11 (32%) converted to CR by the LTFU. High concordance (77% - 79%) was observed for objective response rates (ORR CR + PR) between local and IRC at all times assessed. Landmark analysis of progression-free survival (PFS) by response status (per local) revealed that most of the 60 pts with disease control (stable disease or better) at 3 mo had prolonged disease control with a 73% 12-mo PFS rate. Of the 42 pts with CR and 9 with PR at 3 mo, the 12-mo PFS rates were 79% and 78%, respectively. Conclusions: Treatment with axi-cel induces high response rates in pts with refractory large B cell lymphoma. CR rates increased through the LTFU, suggesting that responses deepen over time and that pts with PR can achieve CR as late as a year post-infusion. ORR at 3 mo may be prognostic for prolonged PFS. Drs Locke and Neelapu contributed equally. Clinical trial information: NCT02348216.Data-cut; median f/u, mos N = 101 BOR, n (%) ORR Concordance, % Local IRC ORR CR ORR CR PA; 8.7 83 (82) 55 (54) 72 (71) 52 (51) 77 YESCARTA USPI; 11.6 84 (83) 55 (54) 73 (72) 52 (51) 79 LTFU; 15.1 84 (83) 59 (58) 73 (72) 52 (51) 79
Locke et al. (Sun,) studied this question.